Pinterest Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Pinterest Inc trades at $18.4 (market cap $11.41B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11.7× Pinterest Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals.
| PINS | VRTX | |
|---|---|---|
Market Cap | $11.41B | $134.06B |
Sector | Media | Health |
52-Week High | $36.49 | $557.96 |
52-Week Low | $15.42 | $376.62 |
Enterprise Value | $11.33B | $128.18B |
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $20.14, down 1.27% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth from $2.8B in 2022 to $4.2B in 2025, though net income margin compressed to 5.46%. Recent CFO resignation and insider selling have weighed on sentiment, while analyst consensus remains bullish with a $28.69 price target representing 42% upside potential.
PINS offers significant upside based on analyst targets but faces near-term headwinds from leadership transition and competitive pressures. The stock's high P/E ratio of 59.24 requires continued execution on AI-driven growth initiatives. Key risks include market share competition and the company's ability to monetize international users effectively while managing rising infrastructure costs from the $4B AWS partnership.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Trailing returns across standard periods
Latest headlines on both assets
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →